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Abstract: Background
Development of a non-endoscopic test for Barrett's esophagus (BE) would
revolutionize population screening and surveillance for patients with BE. Swallowed
cell collection devices have recently been developed to obtain cytology from the
esophagus: automated detection of neoplasia in such samples would enable large-
scale screening and surveillance.
Methods
Fourier Transform infrared spectroscopy (FTIR) was used to develop an automated
tool for detection of BE and Barrett's neoplasia in esophageal cell samples. Cytology
brushings were collected at endoscopy, cytospun onto slides and FTIR images
measured. An automated cell recognition program was developed to identify individual
cells on the slide.
Results
Cytology review and contemporaneous histology was used to inform a training dataset
containing 141 cells from 17 patients. A classification model was constructed using
principal component analysis (PCA) fed linear discriminant analysis (LDA), then tested
using leave one sample out cross validation (LOSOCV). Applying this training model to
whole slide samples, a threshold voting system was used to classify samples
according to their constituent cells. Across the entire dataset of 115 FTIR maps from
66 patients, whole samples were classified with sensitivity and specificity respectively
as follows: normal squamous 79.0% and 81.1%, non-dysplastic Barrett's 31.3% and
100%, and neoplastic Barrett's 83.3% and 62.7%.
Conclusions
Analysis of esophageal cell samples can be performed using FTIR with reasonable
sensitivity for Barrett's neoplasia, though poor specificity with the current technique.
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Response to reviewers 
 
Many thanks for your comments and the opportunity to resubmit our article. Our responses 
are highlighted in red below.  
 
Reviewer #1: I have been asked to review the submitted manuscript entitled "Automated 
cytological detection of Barrett's neoplasia with infrared spectroscopy" by Dr. Old et al.. They 
evaluated the accuracy for cytological diagnosis of Barrett's esophagus, dysplasia, and 
adenocarcinoma using Fourier Transform infrared spectroscopy (FTIR). I agree with the clinical 
importance of automated diagnostic methods of Barrett's metaplasia and carcinoma. FTIR 
looks promising but further investigation seems to be needed. However, there are several 
concerns especially in the study design. 
 
1. The training set have to be separated from the test set. I could not clearly figure out whether 
the 17 patients in training set were included in the whole 66 patients. If the training dataset 
were included in the test set, overfitting results could be shown. Flow diagram should be added 
to explain each cohort. 
 
No spectra included in the training set were included in the test dataset, as stated in the text 
in the section headed ‘Test dataset’ in the Results: 
 
‘Cells that were included in the training dataset were excluded from the test set, to prevent 
overestimation of performance.’ 
 
I have moved this sentence to the Methods section for clarity. The following flow diagram (as 
suggested) could be added immediately after this sentence to aid understanding, however 
we have reached the limit of the number of figures allowed for this manuscript, so I cannot 
attach a further figure. This could be included as Figure 1 (with renaming of later figures) if 
the editors will allow.  
 
 
Response to Reviewers Click here to download Author's Response to Reviewers'
Comments Response to reviewers.docx
 
2. Gold standard for this study should be the pathological diagnosis using biopsy samples. 
Then the diagnostic accuracy should be compared between FTIR and the classical cytological 
diagnosis. 
 
The gold standard for comparison for the test set in this study was the biopsy result, as 
suggested. We have highlighted this with a further sentence in the ‘Test dataset’ section as 
follows: 
 
‘This predicted pathology was compared against the biopsy result from the same region and 
sensitivity and specificity calculated using this gold standard.’ 
 
Not every cell was examined cytologically (there were 5,374 cells in total) as this was felt to 
be impractical. This was however used for every cell included in the training dataset as 
outlined in the ‘Training dataset’ section: 
 
‘cells whose classification on appearance by two cytopathologists was in agreement with 
contemporaneous endoscopy and biopsy from the same region were included.’  
 
3. There is no description that samples of low-grade dysplasia were included in which group. 
 
We have added the following sentence in the ‘Training dataset’ section: 
 
‘The dysplasia/adenocarcinoma group included any degree of dysplasia (low or high grade), 
but samples classified as ‘indefinite for dysplasia’ were excluded.’   
 
4. A scatter plot (like fig. 1) of the test set should be shown. 
 
The analysis of individual cells in the test dataset is more complicated than the training 
dataset: cells in the training set have a known cytological appearance that matches the 
histology taken from the same locus. Since every cell has a known pathology label, a scatter 
plot can be produced using the known label for every cell. In the test dataset, individual cells 
do not have a known pathology label. The pathology of the whole slide is known, but the 
individual cells on the slide may be a heterogeneous population. For this reason we used a 
threshold voting system to assign predicted pathology to whole slide samples based on the 
number of cells per slide of a given predicted pathology. It is not possible to present this data 
with a scatter plot in the same way as Figure 1 of the training dataset.  
 
 
5. It looks difficult to discriminate the three groups at once. Since the diagnostic accuracy for 
normal squamous cells seems to be comparably high, I recommend the diagnostic method 
should be separated into two steps: first, distinguish columnar cells from squamous cells; 
second, distinguish dysplasia/adenocarcinoma from metaplastic cells. Such physiologically 
reasonable strategy might elevate the accuracy. Even if you can achieve good performance 
only in the first step, this could be clinically useful for the screening of high risk group. 
 
We attempted this in our initial analysis and it gave similar results to the 3 group model 
presented in our paper. The results from our initial 2 group model (differentiating normal 
squamous from columnar cells, as suggested by Reviewer 1) were as follows: 
 
 
 
 
 
 
Since the values were similar to those from the 3 group model, and including a further table 
and graph lengthens the paper further, we decided not to present this additional data in our 
manuscript. We have added the following sentence to the discussion to indicate this: 
 
‘A two-stage analysis may be developed whereby cells are initially separated into squamous 
or columnar by a predictive model, and then a further analysis used to separate dysplastic 
and non-dysplastic cells. A two-stage model was attempted using the current dataset, giving 
very similar results to the 3-group model presented here (two-stage results not shown).’  
 
 
Reviewer #2: Summary  
Old et al. developed automated cytological detection of esophageal adenocarcinoma or 
dysplasia in Barrett's esophagus. This paper is a well-written interesting study. 
 
1. Although the authors discussed, reasons why the authors set small number of the training 
dataset of Barrett's esophagus are not clear. 
 
We have elaborated on this further in the Discussion section as follows: 
 
‘The major limiting factor in this study was the small number of cells in the Barrett’s training 
dataset. Small numbers of cells were seen on the Barrett’s cell slides selected for 
cytopathology analysis: this was likely due to suboptimal cell preparation for the relatively 
smaller Barrett’s cells (smaller than squamous or dysplastic cells, which tended to clump 
together on our cell preparation) – a difficulty of optimizing cell preparation and 
centrifugation for different cell types. Additionally, the small Barrett’s cells were more likely 
to be missed by our cell detection algorithm (the binary mask). This left a low number of cells 
that were identified by the binary mask, and also identified by both reporting cytopathologists 
as unequivocally representing Barrett’s cells.’ 
 
 
2. The authors should clearly state that this automated cytological detection is unsuitable for 
Barrett's esophagus screening because of low sensitivity. 
 
The following sentence has been added to the Conclusions: 
 
‘The low sensitivity for non-dysplastic Barrett’s using the present technique is not suitable as 
for screening purposes.’ 
 
 
3. What diagnosis was obtained by FITR spectroscopy in the case of misdiagnosis? 
 
We have inserted the following table as part of Table 4. This confusion matrix shows the 
diagnosis in cases of misclassification. 
 
 
 
 Predicted pathology  
True Pathology NSQ BE DYS/AC TOTALS 
NSQ 15 0 4 19 
BE 7 10 15 32 
DYS/AC 7 0 35 42 
TOTALS 29 10 44 93 
 
 
4. Higher quality of figure 3 is required. 
 
We have reproduced this figure at higher resolution (see figure file uploaded). 
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Abstract 
Background 
Development of a non-endoscopic test for Barrett’s esophagus (BE) would 
revolutionize population screening and surveillance for patients with BE. Swallowed 
cell collection devices have recently been developed to obtain cytology from the 
esophagus: automated detection of neoplasia in such samples would enable large-
scale screening and surveillance. 
Methods 
Fourier Transform infrared spectroscopy (FTIR) was used to develop an automated 
tool for detection of BE and Barrett’s neoplasia in esophageal cell samples. Cytology 
brushings were collected at endoscopy, cytospun onto slides and FTIR images 
measured. An automated cell recognition program was developed to identify 
individual cells on the slide. 
Results 
Cytology review and contemporaneous histology was used to inform a training 
dataset containing 141 cells from 17 patients. A classification model was constructed 
using principal component analysis (PCA) fed linear discriminant analysis (LDA), 
then tested using leave one sample out cross validation (LOSOCV). Applying this 
training model to whole slide samples, a threshold voting system was used to 
classify samples according to their constituent cells. Across the entire dataset of 115 
FTIR maps from 66 patients, whole samples were classified with sensitivity and 
specificity respectively as follows: normal squamous 79.0% and 81.1%, non-
dysplastic Barrett’s 31.3% and 100%, and neoplastic Barrett’s 83.3% and 62.7%.  
Conclusions 
Analysis of esophageal cell samples can be performed using FTIR with reasonable 
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sensitivity for Barrett’s neoplasia, though poor specificity with the current technique. 
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BACKGROUND 
The current British Society of Gastroenterology (BSG) guidelines list several future 
developments that would ‘revolutionize the care of individuals with Barrett’s 
esophagus and should be priorities for policy makers and funders’, of which the 
number one item listed is ‘a non-endoscopic test(s) for diagnosis and surveillance’ 
[1]. Development of an accurate, minimally invasive, relatively low-cost test could 
radically alter current models of endoscopic surveillance, and overcome the greatest 
obstacles to screening for Barrett’s, namely the cost, acceptability and risks of 
endoscopy.  
Swallowed cell collection devices offer a potential non-endoscopic means of 
sampling from the esophagus. Balloon collection devices have been used in eastern 
Asia for several decades as a screening tool for squamous cell carcinoma of the 
esophagus [2–4]. A balloon device has been trialed for Barrett’s-associated 
neoplasia, but challenges included inadequate cell collection and reduced sensitivity 
for dysplasia [5]. Results from the same study suggested that brush cytology has the 
potential to collect a representative sample, but the difficulty of interpretation of low 
grade dysplasia may limit the sensitivity using conventional cytological assessment. 
If a swallowed cell collection device were to be used as a screening tool for Barrett’s 
this would pose a number of challenges for conventional cytological assessment. 
Firstly, esophageal cytology is performed relatively infrequently, and expertise in this 
field is correspondingly limited. Secondly, assessment of cells may be challenging 
and shows variable correlation with histology taken contemporaneously [6–8]. 
Thirdly, a swallowed device that enters the stomach may have glandular cells from 
the stomach and these must be differentiated from esophageal glandular metaplasia. 
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Fourthly, if expert cytological assessment were required for every sample collected 
as part of population screening, this would require significant resources.  
The recently developed Cytosponge™ device aims to overcome a number of these 
challenges through immunostaining with Trefoil Factor 3 (TFF3), with promising 
results for detection of BE [9,10]. 
An alternative approach to conventional cytological cell classification uses Fourier 
Transform infrared spectroscopy (FTIR). In FTIR spectroscopy, infrared radiation is 
passed through a sample. Some of the infrared radiation is absorbed by the sample 
and some of it passes through (i.e. it is transmitted). The resulting spectrum 
represents the molecular absorption and transmission, creating a molecular 
fingerprint of the sample based on its biomolecular composition. This makes infrared 
spectroscopy useful for several types of analysis. 
Subtle variations in sample biochemistry can be detected, highlighting different 
pathology states, and FTIR spectra can be used to build classification models to 
assign pathology labels to a range of biomedical samples [11].  
To date there have been a small number of studies showing the ability of FTIR 
spectroscopy to classify BE using esophageal tissue [12–14], and only one small 
study showing feasibility in detection of BE using esophageal cells [15].  The present 
study was designed as a larger study to evaluate FTIR as a means for detecting 
Barrett’s neoplasia in esophageal cells from brush cytology samples.  
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METHODS 
Sample collection 
Although the long term goal is non-endoscopic cell collection, samples in this study 
were taken under direct vision at endoscopy to allow contemporaneous biopsy and  
rigorous inclusion criteria to inform a training dataset.  
Ethical approval was obtained for this study and all patients participating in the study 
provided informed consent. Samples were collected from patients undergoing 
scheduled endoscopy for Barrett’s surveillance. In order to enrich the sample 
population for patients with esophageal adenocarcinoma, some samples were also 
collected from patients undergoing surgery for esophageal cancer. Normal 
esophageal squamous cells, used as controls, were collected from patients 
undergoing routine endoscopy in whom no endoscopic or histological abnormality 
was identified.  
Cytology samples were collected at endoscopy using an endoscopic cytology brush 
passed down the instrument channel of an endoscope, under direct vision at 
endoscopy. The cytology brush containing the cells was then stored in formalin at 
room temperature until slide preparation.  
In order to be certain that cells included in the training dataset were representative of 
the specified pathology, a biopsy was taken from the area after cell collection, and 
only those cells whose cytological appearance was consistent (on review by two 
cytopathologists) with the contemporaneous endoscopy and biopsy results were 
included. In cases where the cytology and histology results did not agree, the cells 
were not included in the training model.  
For later analysis of whole samples included in the test dataset, the classification of 
the whole sample was based on the endoscopy and biopsy result as the gold 
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standard. To remove further the possibility of misclassification, patients were only 
included in the test dataset if they had no history of more advanced disease i.e. to be 
included as a normal control they must have no history of BE, and to be included as 
a BE case they must have no history of esophageal dysplasia/adenocarcinoma.  
 
Sample measurement 
Cell samples were transferred to calcium fluoride slides for measurement; a detailed 
protocol of this procedure is included in Appendix A of the Electronic Supplementary 
Material.  
Samples were measured at the Biophotonics Unit at Gloucestershire Royal Hospital 
using a Perkin Elmer Spectrum One FTIR spectrometer with a Perkin Elmer 
Spotlight 400 imaging system. Infrared absorption maps were obtained in 
transmission mode, raster scanning at 6.25m per pixel, using 4cm-1 spectral 
resolution across a wavenumber range of 750-4000cm-1. An initial background 
reading was taken using 120 scans per pixel from an acellular region of the slide. 
Maps of infrared absorption were collected across a 4mm x 2mm region of each 
slide, measuring 2 scans per pixel.  
 
Data processing: automated identification of cells 
Our intention was to develop a system that used mapping to measure large areas 
and then automatically identify cells within the measured region.  An automated 
measurement system could then be used to analyze cells on a slide without having 
to visually identify and measure each cell individually.  
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Initial data processing steps were applied to enhance signal to noise ratios in the 
measured cell spectra, and prepare spectra for further analysis.  
A post-processing algorithm was developed to detect cellular regions and extract the 
spectra from this region, assigning it to a particular cell. The spectra measured from 
each individual cell could then be analyzed and a classification label assigned to that 
particular cell. The pre-processing steps and post-processing algorithm are 
described further in Appendix B of the Electronic Supplementary Material. Similar 
techniques have been described previously by a number of authors [16–18]. 
 
Developing a training dataset 
The training dataset was composed of cells from a preliminary group of patients. 
After identification by the binary mask algorithm, cells whose classification on 
appearance by two cytopathologists was in agreement with contemporaneous 
endoscopy and biopsy from the same region were included. The 
dysplasia/adenocarcinoma group included any degree of dysplasia (low or high 
grade), but samples classified as ‘indefinite for dysplasia’ were excluded.   
Multivariate analysis was then performed to identify spectral differences between 
cells from the different pathology groups to enable classification based on cell 
spectra. Principal component analysis (PCA) was used to identify variance between 
the spectra and reduce the complexity of the dataset. Linear discriminant analysis 
(LDA) was then used to incorporate information about which pathology groups the 
spectra came from, and build diagnostic classification models. Diagnostic 
classification models were then tested using leave-one-sample-out-cross validation 
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(LOSOCV): each sample is sequentially tested in training models that contains data 
from every sample except the one being tested.  
Classification models developed using the training dataset could then be applied to 
the full dataset, to classify whole samples from individual patients. Cells that were 
included in the training dataset were excluded from the test set, to prevent 
overestimation of performance.  
Since not every cell on a slide would necessarily have the same classification, a 
‘threshold voting’ system was used to assign a classification to a given sample. For 
example, a 30% threshold per cell would mean that, if 30% or more spectra from that 
cell were classified as dysplastic, the entire cell is classified as dysplastic. Similarly, 
if 30% of cells on a slide are found to be dysplastic the sample is classified as 
dysplastic. This is a higher threshold than that used by cytologists, whereby the 
presence of any dysplasia is sufficient for classification as dysplastic, but aimed to 
ensure higher specificity when very large numbers of cells were being tested for 
each patient.  
 
RESULTS 
Training dataset 
The training dataset was developed using 141 cells from 17 patients (8 normal 
squamous, 4 BE, 5 dysplasia/adenocarcinoma), with a total of 1,480 spectra. The 
data included in the training dataset are shown in Table 1.  
A classification model was constructed using PCA-fed LDA. The linear discriminant 
functions are shown in Figure 1. LDA achieves good grouping and separation of 
each of the pathology groups, but there remains a cluster of BE datapoints close to 
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the other two groups. Every one of these outlying datapoints was from a single 
sample.  
 
Table 1 Summary of data included in the training dataset. 
 No. of patients No. of cell regions No. of spectra for 
analysis 
NSQ 8 22 726 
BE 4 12 76 
DYS/AC 5 22 678 
TOTAL 17 56 1,480 
NSQ normal squamous; BE Barrett’s esophagus; DYS/AC 
dysplasia/adenocarcinoma 
 
 
TAKE IN FIGURE 1 
 
Figure 1 Scatter plot of all spectra in training dataset, plotted by linear discriminant 
(LD) function. NSQ = normal squamous, Barrett’s = Barrett’s esophagus, Adenoca. = 
adenocarcinoma. 
The performance of the training dataset classification model was then tested using 
LOSOCV: the results are shown in Table 2.  
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Table 2 Performance of the training cells 3 group classification model 
 NSQ BE DYS/AC 
Sensitivity % (SD) 83.6 (5.2) 62.8 (0.8) 69.5 (4.5) 
Specificity % (SD) 70.8 (3.8) 97.5 (0.9) 87.8 (3.5) 
SD standard deviation; NSQ normal squamous; BE Barrett’s esophagus; DYS/AC 
dysplasia/ adenocarcinoma. 
 
The sensitivity of the model for individual spectra is reasonably good for normal 
squamous cells at 83.6%, but only moderate for the Barrett’s and 
dysplasia/adenocarcinoma cells. The standard deviation was largest for the normal 
squamous cells, as would be expected since the cells chosen were different for each 
iteration. The size of the variation in the sensitivity for the dysplasia/adenocarcinoma 
group reflects the overlap with the normal squamous cells and hence this varies 
depending on which cells are included. There was very little variation in the Barrett’s 
result, with a small standard deviation.  
 
Spectral differences between pathology groups 
The mean spectra from each of the three pathology groups are shown in Figure 2 
below. The spectra are presented as second derivatives in order to clarify the 
position of spectral peaks and highlight differences between the groups.  
 
TAKE IN FIGURE 2 
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Figure 2 Second derivative of the mean spectra from A) NSQ B) BE C) DYS/AC, 
with the text color indicating the likely biomolecule mainly responsible for that peak. 
NSQ normal squamous; BE Barrett’s esophagus; DYS/AC 
dysplasia/adenocarcinoma. Green = glycogen, blue = glycoprotein, red = DNA, Black 
= amino acid/protein, Purple = mixed contributions/multiple possibilities. 
 
Assigning biochemical labels to spectral peaks is tentative, as there are frequently 
multiple possible bond vibrations that can give a spectral peak at a given 
wavenumber. However, based on previous studies in esophageal tissue [12–14] and 
previous work by the group in esophageal tissue [19], there are a number of 
important differences seen between the pathology groups in this study. 
The BE and dysplasia/adenocarcinoma groups have an additional spectral peak at 
969cm-1 that probably represents DNA, and may reflect a higher DNA content in 
these cell types.  
At one of the key glycoprotein regions around 1080cm-1, the BE group shows a 
doublet with peaks at 1067 and 1084cm-1, whereas the normal squamous and 
dysplasia/adenocarcinoma groups have a single peak at 1077cm-1. This may be due 
to differences/increase in mucin content within the BE cells.  
There are three peaks corresponding to glycogen in the normal squamous cells at 
995, 1024 and 1153cm-1: these peaks are either smaller or show different 
configurations in the BE and dysplasia/adenocarcinoma groups, which may reflect a 
lower glycogen content in these cell, as might be expected with their pathological 
state. 
 
Test dataset 
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The classification model developed from the training dataset was then applied to the 
full dataset. The steps involved are illustrated in Figure 3: first the binary mask 
algorithm was used to identify individual cells on each slide, then the classification 
model applied to assign a pathology label to each cell on the slide based on its FTIR 
spectra, then an overall pathology classification given to each slide. This predicted 
pathology was compared against the biopsy result from the same region and 
sensitivity and specificity calculated using this gold standard.  
 
TAKE IN FIGURE 3 
Figure 3 Steps involved in assigning pathology labels to every cell A) unstained 
slide, B) binary mask identifies cell regions, C) training model applied to cells to 
assign pathology label.  
The number of samples and spectra included in the test dataset (after the same pre-
processing steps as those applied to the training dataset) are shown in Table 3.  
 
Table 3 Total number of samples included in the test dataset 
 No. of 
patients 
No. of FTIR 
maps 
No. of cell 
regions 
No. of spectra 
for analysis 
NSQ 18 19 722 27,662 
BE 21 32 1,891 48,322 
DYS/AC 25 42 2,620 54,418 
TOTAL 64 93 5,233 130,402 
NSQ normal squamous; BE Barrett’s esophagus; DYS/AC dysplasia/ 
adenocarcinoma. 
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The results from application of the training model to this test dataset are shown in 
Table 4.  
 
Table 4 Classification performance of the training model applied to the whole 
samples as a test dataset. A voting threshold was used for classifying each 
individual cell on a slide (30% threshold) and for classifying the sample overall (30% 
threshold). Table 4A shows the sensitivity and specificity, whilst Table 4B shows the 
confusion matrix, showing the prediction for every sample. NSQ normal squamous; 
BE Barrett’s esophagus; DYS/AC dysplasia/ adenocarcinoma. 
A 
 NSQ BE DYS/AC 
Sensitivity % 79.0 31.3 83.3 
Specificity % 81.1 100 62.7 
 
B 
 Predicted pathology  
True Pathology NSQ BE DYS/AC TOTALS 
NSQ 15 0 4 19 
BE 7 10 15 32 
DYS/AC 7 0 35 42 
TOTALS 29 10 44 93 
 
 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
Overall, the detection of normal squamous and dysplasia/adenocarcinoma samples 
was reasonably good, with a sensitivity of 79.0% and 83.3% respectively. Specificity 
for dysplasia/adenocarcinoma was low at 62.7%, and detection of Barrett’s was 
poor, with only 31.3% of samples classified correctly.  
 
DISCUSSION 
FTIR was investigated as a means of identifying Barrett’s esophagus and associated 
neoplasia in esophageal cells, for potential use in conjunction with a non-endoscopic 
cell collection device. In this study, a good classification performance was seen for 
normal squamous samples (sensitivity 79.0%), and dysplasia/ adenocarcinoma 
(83.3%), but the identification of BE samples was poor (sensitivity 31.3%). 
This was based on the application of a training model with the ability to classify 
individual spectra from the training dataset with sensitivity (after cross-validation) 
83.6% for normal squamous cells, 62.8% for BE, and 69.5% for dysplasia/ 
adenocarcinoma.  
Certain key differences were seen between the mean spectra from the different 
pathology groups, that were consistent with possible biochemical differences 
between the cells. These included a higher glycogen content in normal squamous 
cells, altered mucin content in BE cells, and higher DNA content in both BE and 
dysplastic/ adenocarcinoma cells compared to normal squamous cells.  
Nonetheless there are several reasons why the results for the BE cells may have 
been poor. The major limiting factor in this study was the small number of cells in the 
Barrett’s training dataset. Small numbers of cells were seen on the Barrett’s cell 
slides selected for cytopathology analysis: this was likely due to suboptimal cell 
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preparation for the relatively smaller Barrett’s cells (smaller than squamous or 
dysplastic cells, which tended to clump together on our cell preparation) – a difficulty 
of optimizing cell preparation and centrifugation for different cell types. Additionally, 
the small Barrett’s cells were more likely to be missed by our cell detection algorithm 
(the binary mask). This left a low number of cells that were identified by the binary 
mask, and also identified by both reporting cytopathologists as unequivocally 
representing Barrett’s cells.  
Not only did the Barrett’s group have the smallest number of cells, but these tended 
to be small, isolated cells (rather than a cluster of cells of the same type), and thus 
contained very few total spectra (76 in this group, versus 678 in the dysplasia group, 
and 726 in the normal squamous). The training model is therefore skewed away from 
classifying spectra into the Barrett’s group, and the Barrett’s group can also more 
readily be affected by a small number of outlying spectra. This makes the Barrett’s 
dataset prone to strong influence from differences due to individual samples or 
patients rather than true biochemical differences due to pathology.  
High numbers of squamous cells were noted on many samples taken only from 
glandular regions of esophagus. It is possible that this resulted from sampling only 
the most superficial cells, which may include squamous cells that originated more 
proximally in the esophagus that have sloughed off and been deposited more distally 
over a glandular region.  
Given the presence of squamous cells seen on many slides, the relative 
homogeneity of the results is perhaps surprising.  Whilst it is possible that artefact in 
the form of ‘between-patient’ differences (as opposed to true pathological 
differences) contribute to this, the small number of patients in the training model 
relative to the test dataset makes this explanation insufficient. A further possibility is 
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that biochemical changes precedes a morphological change in cell appearance. If a 
region of dysplasia or adenocarcinoma underwent a field change (probably reflecting 
genetic change) that preceded phenotypic change in the cells, there may be a 
detectable biochemical difference in cells that appear squamous. Thus spectroscopy 
may be able to provide insights into biochemical changes not detectable with 
conventional microscopy.  
Interestingly, a similar finding was reported in the largest study to date of IR 
spectroscopy for cell classification in cervical samples: Gajjar et al. [20] found that 
their results correlated poorly with conventional cytology, but showed better 
correlation with contemporaneous histology from the same region. This paper cites 
poor cytology sensitivity and specificity as the reason for this, but an analogous 
explanation of field change that has not occurred in every cell (and again, particularly 
in the superficial cells), is another possibility.  
This finding is corroborated by the only previous study of FTIR using esophageal 
cells [15], in which cells that appeared squamous classified according to the 
underlying tissue histology. This consistent finding therefore supports the theory that 
genetic and biochemical change may precede morphological change in some cells.  
In this small study of 10 samples, Townsend et al. reported very high accuracy for 
classification of Barrett’s and dysplasia. They reported a sensitivity to detect Barrett’s 
versus normal squamous of 95.5%, normal squamous versus dysplasia 93.4%, and 
Barrett’s versus dysplasia 88.7%. However, spectra from the same patients were 
included in both test and training datasets, and since these results are drawn from a 
very small number of patients it is possible that ‘between patient’ differences (as 
opposed to ‘between pathology’ differences) contributed to this result.  
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The discriminatory spectral features seen in the work by Townsend et al. are similar 
to the findings seen in the inverse second derivative spectra in our study and also 
correlate with the findings from our tissue mapping study [19] and previous FTIR 
work in the esophagus [12–14]. For example, the amide I peak at around 1650cm-1 
is strongest in the normal squamous group, the DNA peak at 1235cm-1 is strongest 
in the dysplastic cells, and the glycogen peak at 1020cm-1 is strongest in the normal 
squamous cells and almost absent in the dysplasia group. This strengthens the 
findings in their study, and lends further weight to an argument for an underlying 
biochemical difference between the pathology groups, as seen in our analysis of the 
inverse second derivative spectra.  
There have been a small number of other studies using FTIR to classify cell 
pathology with similar methodology. These have shown the ability to classify 
squamous cell samples from the cervix, urinary tract and head and neck 
[16,17,20,21], although this work focused on proof of concept and spectral 
differences, and did not publish equivalent figures for sensitivity and specificity. 
The first trial data (BEST2) from use of the Cytosponge™ found overall sensitivity for 
detecting Barrett’s 79.9%, with this figure increasing to 87.2% in those with ≥3cm of 
circumferential Barrett’s, and a specificity of 92.4% [9]. This is comparable to the 
sensitivity seen in our study for normal squamous (79.0%) or 
dysplasia/adenocarcinoma (83.3%). The BEST2 study did not attempt to 
discriminate dysplasia, but there are plans for future work to incorporate risk 
stratification using DNA analysis for p53 mutations.   
Identification of Barrett’s/dysplasia in combination is sufficient if used solely as a 
screening tool to identify those who require endoscopy. However, reliable detection 
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of dysplasia could potentially replace endoscopic surveillance. The results of our 
study suggest that this may be achievable with FTIR spectral analysis of cells. 
However, this is a multistep technique which requires further optimization and 
validation in combination with a non-endoscopic collection device such as 
Cytosponge™. 
The major source of variability in this study was the widely varying cell density in 
slide samples. Further optimization of techniques for brushing, fixative and 
centrifugation may improve this [22].  
There is much potential to refine the binary mask with a combination of further 
spectral information and size criteria to give a highly accurate cell identification tool. 
One approach could use a spectral marker of DNA (e.g. the 1234cm-1 peak) to 
identify cell nuclei, in combination with associated cell cytoplasm (represented by the 
1650cm-1 peak). This could be used in combination with size criteria to quantify the 
amount of nuclear material present.  
A two-stage analysis may be developed whereby cells are initially separated into 
squamous or columnar by a predictive model, and then a further analysis used to 
separate dysplastic and non-dysplastic cells. A two-stage model was attempted 
using the current dataset, giving very similar results to the 3-group model presented 
here (two-stage results not shown).  
Whilst this study used samples collected at endoscopy in order to enable histological 
and endoscopic validation, there may be further challenges using a non-endoscopic 
cell collection device that collects from the stomach and entire esophagus. The issue 
of differentiating pathological glandular cells from stomach cells was not examined in 
the present study. 
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Another obstacle to clinical implementation is the time needed for sample 
measurement. If a faster automated cell detection process could be used prior to 
infrared measurement, this would avoid measuring large regions that do not contain 
cells, and focus solely on collecting useful spectra.  
Cytopathology review is a further potential source of error. In this study it was 
performed by two cytopathologists together, not independently. Additionally, 
cytopathologists are not used to reviewing single cells in isolation, but more usually 
look at a whole sample for assessment. Presentation of cells in isolation could mean 
the decision is affected by variable staining between slides, which might be 
accounted for by taking the slide as a whole.  
One of the major obstacles to future work in this area is obtaining a reliable gold 
standard against which to test the training model. The poor sensitivity and specificity 
in comparable fields (e.g. cervical cytology) suggests that this may limit the 
usefulness of cytology as a gold standard. Comparing against histology (as in the 
whole sample test dataset) may be more accurate.  
Although the relatively poor sensitivity and specificity of cytology causes problems 
for testing, this supports an argument for developing spectral cytopathology since 
this an area in which diagnostic performance could readily be improved. This 
technology could potentially be applied in a range of different pathologies and organ 
systems. 
 
Conclusions 
FTIR offers a potential automated method of identifying Barrett’s neoplasia in 
esophageal cell samples. Accurate identification of neoplasia could augment or 
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replace current models of endoscopic surveillance. High sensitivity for neoplasia 
would be a key feature if used in clinical practice, but further work is needed to 
optimize the current technique and improve specificity prior to clinical translation. 
The low sensitivity for non-dysplastic Barrett’s using the present technique is not 
suitable for screening purposes.   
  
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
Acknowledgements: 
The authors would like to thank Doug Townsend and Max Diem from Northeastern 
University, Boston, for all their advice on many technical aspects of spectral 
cytopathology.  
Oliver Old was in receipt of a Royal College of Surgeons of England Surgical 
Research Fellowship during this study. 
 
 
 
  
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
References 
 
1. Fitzgerald RC, di Pietro M, Ragunath K, Ang Y, Kang J-Y, Watson P, et al. British 
Society of Gastroenterology guidelines on the diagnosis and management of 
Barrett’s oesophagus. Gut. 2014;63:7–42.  
2. Shu YJ. Cytopathology of the esophagus. An overview of esophageal 
cytopathology in China. Acta Cytol. 1983;27:7–16.  
3. Dawsey SM, Shen Q, Nieberg RK, Liu SF, English SA, Cao J, et al. Studies of 
esophageal balloon cytology in Linxian, China. Cancer Epidemiol. Biomarkers Prev. 
1997;6:121–30.  
4. Spechler S. Barrett’s esophagus: Should we brush off this ballooning problem? 
Gastroenterology. 1997;112:2138–42.  
5. Falk GW, Chittajallu R, Goldblum JR, Biscotti C V, Geisinger KIMR, Petras RE, et 
al. Surveillance of Patients With Barrett ’ s Esophagus for. 1997;1787–97.  
6. Hughes JH, Ph D, Cohen MB. Is the Cytologic Diagnosis of Esophageal Glandular 
Dysplasia Feasible ? 1998;18:312–6.  
7. Geisinger KR, Teot LA, Richter JE. A comparative cytopathologic and histologic 
study of atypia, dysplasia, and adenocarcinoma in Barrett’s esophagus. Cancer. 
1992;69:8–16.  
8. Hardwick RH, Morgan RJ, Warren BF, Lott M, Alderson D. Brush cytology in the 
diagnosis of neoplasia in Barrett’s esophagus. Dis. Esophagus. 1997;10:233–7.  
9. Ross-Innes CS, Debiram-Beecham I, O’Donovan M, Walker E, Varghese S, Lao-
Sirieix P, et al. Evaluation of a Minimally Invasive Cell Sampling Device Coupled with 
Assessment of Trefoil Factor 3 Expression for Diagnosing Barrett’s Esophagus: A 
Multi-Center Case–Control Study. Franco EL, editor. PLOS Med. 2015;12:e1001780.  
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
10. Kadri SR, Lao-Sirieix P, O’Donovan M, Debiram I, Das M, Blazeby JM, et al. 
Acceptability and accuracy of a non-endoscopic screening test for Barrett’s 
oesophagus in primary care: cohort study. BMJ. 2010;341:c4372.  
11. Old O, Fullwood L, Scott R, Lloyd G, Almond L, NShepherd N, et al. Vibrational 
Spectroscopy for cancer diagnostics. Anal. methods. 2014;6:3901–17.  
12. Wang TD, Triadafilopoulos G, Crawford JM, Dixon LR, Bhandari T, Sahbaie P, et 
al. Detection of endogenous biomolecules in Barrett’s esophagus by Fourier 
transform infrared spectroscopy. Proc. Natl. Acad. Sci. U. S. A. 2007;104:15864–9.  
13. Quaroni L, Casson AG. Characterization of Barrett esophagus and esophageal 
adenocarcinoma by Fourier-transform infrared microscopy. Analyst. 2009;134:1240–
6.  
14. Amrania H, Antonacci G, Chan C-H, Drummond L, Otto WR, Wright N a, et al. 
Digistain: a digital staining instrument for histopathology. Opt. Express. 
2012;20:7290–9.  
15. Townsend D, Miljković M, Bird B, Lenau K, Old O, Almond M, et al. Infrared 
micro-spectroscopy for cyto-pathological classification of esophageal cells. Analyst. 
2015;140:2215–23.  
16. Schubert JM, Bird B, Papamarkakis K, Miljković M, Bedrossian K, Laver N, et al. 
Spectral cytopathology of cervical samples: detecting cellular abnormalities in 
cytologically normal cells. Lab. Invest. 2010;90:1068–77.  
17. Papamarkakis K, Bird B, Schubert JM, Miljković M, Wein R, Bedrossian K, et al. 
Cytopathology by optical methods: spectral cytopathology of the oral mucosa. Lab. 
Invest. 2010;90:589–98.  
18. Miljković M, Bird B, Lenau K, Mazur AI, Diem M. Spectral cytopathology: new 
aspects of data collection, manipulation and confounding effects. Analyst. 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
2013;138:3975–82.  
19. Old OJ, Lloyd GR, Nallala J, Isabelle M, Almond LM, Shepherd NA, et al. Rapid 
infrared mapping for highly accurate automated histology in Barrett’s oesophagus. 
Analyst. 2016;  
20. Gajjar K, Ahmadzai A a, Valasoulis G, Trevisan J, Founta C, Nasioutziki M, et al. 
Histology verification demonstrates that biospectroscopy analysis of cervical cytology 
identifies underlying disease more accurately than conventional screening: removing 
the confounder of discordance. PLoS One. 2014;9:e82416.  
21. Bird B, Romeo MJ, Diem M, Bedrossian K, Laver N, Naber S. Cytology by 
Infrared Micro-Spectroscopy: Automatic Distinction of Cell Types in Urinary Cytology. 
Vib. Spectrosc. 2008;48:101–6.  
22. Baker MJ, Trevisan J, Bassan P, Bhargava R, Butler HJ, Dorling KM, et al. Using 
Fourier transform IR spectroscopy to analyze biological materials. Nat. Protoc. 
2014;9:1771–91.  
23. Bassan P, Byrne HJ, Bonnier F, Lee J, Dumas P, Gardner P. Resonant Mie 
scattering in infrared spectroscopy of biological materials--understanding the 
“dispersion artefact”. Analyst. 2009;134:1586–93.  
24. Bassan P, Kohler A, Martens H, Lee J, Byrne HJ, Dumas P, et al. Resonant Mie 
scattering (RMieS) correction of infrared spectra from highly scattering biological 
samples. Analyst. 2010;135:268–77.  
 
 
  
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
Figure 1 Click here to download Figure Figure 1 v2.pdf 
AB
C
Figure 2 Click here to download Figure FIGURE 2.pdf 
	A	
	
B	
	
C	
	
	
	
Figure 3 Click here to download Figure Revised Figure 3.pdf 
  
Supplementary Material (Electric Supplementary Material)
Click here to access/download
Supplementary Material (Electric Supplementary
Material)
ELECTRONIC SUPPLEMENTARY MATERIAL.docx
  
Figure 4 Supplementary Material (Electric Supplementary Material)
Click here to access/download
Supplementary Material (Electric Supplementary
Material)
Figure 4 v2.pdf
  
Certification Form
Click here to access/download
Certification Form
Certification form signed by all.pdf
 
 The Japanese Society of Gastroenterology (JSGE) 
 
 Journal of Gastroenterology  
Conflict of Interest Disclosure Statement Form 
 
 
The corresponding author should upload the form online.  
 
When submitting a manuscript to the Journal of Gastroenterology, all authors are required to disclose any 
financial relationship (within the last 2 years) with a biotechnology manufacturer, a pharmaceutical 
company, or other commercial entity that has an interest in the subject matter or materials discussed in 
the manuscript. The matters requiring disclosure are outlined in the JSGE Conflict of Interest Policy. 
 
Disclosed Potential Conflict of Interest 
1. Employment/Leadership position/ Advisory role  (1,000,000 yen or more) 
2. Stock ownership or options (Profit of 1,000,000 yen or more/ownership of 5% or more of total 
shares) 
3. Patent royalties/licensing fees (1,000,000 yen or more) 
4. Honoraria (e.g. lecture fees) (1,000,000 yen or more) 
5. Fees for promotional materials (e.g. manuscript fee) (1,000,000 yen or more) 
6. Commercial research funding (2,000,000 yen or more) 
7. Others (e.g. trips, travel, or gifts, which are not related to research, education and medical 
practice) (50,000 yen or more) 
 
 
If any of the above items (1 to 7) apply to author(s) of the article, the corresponding author should 
provide the statement in the space below by using the following examples for each author. 
“A (author name) received a research grant from Z; B serves as a consultant to Y (entity name); C 
received lecture fees from X; D received honoraria for writing promotional material for W;E holds a 
patent on V; F’s spouse is chairman of U.” 
 
If none of the authors have a relationship matching the above listed items (1 to 7), please provide the 
statement: “The authors declare that they have no conflict of interest” in the space below. 
 
 
The authors declare that they have no conflict of interest. 
 
 
When your manuscript is accepted for publication, all of the disclosures will appear in your article as a 
“Conflict of Interest Statement” in the Journal of Gastroenterology. 
Conflict of Interest Disclosure Statement Click here to download Conflict of Interest Disclosure
Statement COI form.docx
